Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
Around one in three people with severe depression don't get better with standard treatments; this is called treatment-resistant depression. Psilocybin, a natural compound found in some mushrooms, shows early promise as a new approach for this type of depression. Scientists think it makes the brain more flexible, but it might also reduce inflammation in the body. We know that inflammation can be linked to depression, especially when treatments don't work well. This study will examine blood samples from people who took part in a previous trial involving psilocybin for depression. Researchers will measure levels of inflammation markers to see how they change and if these changes are linked to how well psilocybin works. Understanding this could help doctors decide who might benefit most from psychedelic therapies.
At a glance
What is this study about?
For many people living with depression, standard treatments like antidepressants work well. However, about a third of individuals with severe depression find that these treatments don't help them enough. This is known as treatment-resistant depression, and it can be a very challenging condition, impacting daily life and increasing risks.
Researchers are exploring new ways to help, and one area of interest is psilocybin, a natural compound found in certain mushrooms. Early studies suggest it might offer a fresh approach for people with this hard-to-treat depression. While it's thought to help by making the brain more flexible, another idea is that it could also affect the body's immune system, specifically by reducing inflammation. We know that higher levels of inflammation in the body have been linked to depression, particularly when treatments aren't working.
This study aims to discover if psilocybin changes these inflammation levels and if those changes are connected to how much a person's depression improves. To do this, scientists will look at blood samples from people who previously took part in a psilocybin trial. They'll measure specific inflammation markers in these samples. Understanding this link could be very important, helping doctors better understand how psilocybin works and, in the future, identifying which patients might benefit most from this kind of treatment.
Key takeaways
- Around 1 in 3 people with major depression don't respond to usual treatments.
- Psilocybin (from some mushrooms) is being explored as a new way to help.
- This study investigates if psilocybin reduces inflammation in the body.
- Inflammation might be linked to depression that's hard to treat.
- Findings could help doctors understand how psilocybin works and who might benefit most.
Who may be eligible?
This study is looking back at blood samples from people who have already taken part in a clinical trial. Therefore, it's not recruiting new participants. However, the original trial that provided these blood samples was for people with major depression that hadn't improved with typical treatments.
Generally, those who took part in the original study were fluent in English, and their depression had been properly diagnosed. They would have tried at least two different antidepressant medications without success, or one medication and a course of talking therapy. Participants needed to be between 25 and 80 years old, and if they were over 60, their depression must have started before that age.
People were not eligible if they had other serious mental health conditions like bipolar disorder, a psychotic disorder (other than certain drug-related ones), a history of severe drug or alcohol dependence, or specific personality disorders. Also, anyone who had attempted suicide in the recent past would not have been able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 25 to 80 years old?
- Do you have major depression that hasn't responded to standard treatments?
- Have you been diagnosed with major depression by a health professional?
- Do you *not* have a history of bipolar disorder or psychosis?
- Is your first episode of depression before age 60 (if you are currently over 60)?
What does participation involve?
This particular study involves looking at existing blood samples from a previous trial, so there are no direct participation requirements for new individuals. The researchers will be analyzing these lab samples to measure specific markers related to inflammation at different time points.
Potential risks and benefits
Locations (1)
- King's College London Institute of Psychiatry, Psychology and NeuroscienceVerified postcodeLondon, United Kingdom
Common questions
What is treatment-resistant depression?
It's when someone's major depression hasn't gotten much better after trying at least two different standard antidepressant treatments.
What is psilocybin?
Psilocybin is a natural compound found in certain types of mushrooms that is being studied for its potential effects on mental health.
What does 'inflammation' have to do with depression?
Some research suggests that ongoing inflammation in the body might play a role in depression, especially when other treatments haven't worked well.
Will this study help me get psilocybin for my depression?
No, this specific study is analyzing blood samples that have already been collected. It's research to understand how psilocybin works, not a treatment trial for new participants.
What are 'inflammatory markers'?
These are substances in the blood that can show if there's inflammation in the body. Researchers will measure these to see if psilocybin changes them.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.